Abstract Library

#4564 Vasculogenic mimicry in neuroendocrine tumour across different primary sites

Introduction: Anti-angiogenesis treatments targeting VEGFRs, including Surufatinib and Cabozantinib, etc. showed better efficacy for pancreatic neuroendocrine tumours (NET) than NET of other primary sites. Recent clinical trial targeting tumour necrosis factor receptor-associated protein-1, leading to inhibition of vasculogenic mimicry (VM) showed contrary results to current VEGFRs-targeted treatments. However, VM of NET across different primary sites are yet to be understood.

Conference:

Presenting Author: Chen L

Authors: Chen L, Liang Y, Huang D, Ji S, Chen J,

Keywords: neuroendocrine tumour, pancreatic, extra-pancreatic, vasculogenic mimicry,

#4399 Updated data from a single-arm, open-label, multicentre clinical study on the efficacy and safety of surufatinib combined with EP regimen and serplulimab in first-line treatment of NEC

Introduction: NEC is an aggressive neuroendocrine neoplasm with limited treatment options. Surufatinib (SUR), a kinase inhibitor targeting VEGFRs, FGFR-1, and CSF-1R, improves vascular normalisation and tumour microenvironment, synergising with chemo- and immunotherapy.

Conference:

Presenting Author: Lin Z

Authors: Zhang T, Lin Z, Zhao L, Ma H, Zhang D,

Keywords: NEC, surufatinib, EP, first-line,

#4396 Hypoxic microenvironment in neuroendocrine tumours

Introduction: The hypoxic microenvironment is a hallmark of many solid tumours, including neuroendocrine tumours (NETs). Hypoxia plays a crucial role in tumour progression, metastasis, and therapy resistance. However, the specific mechanisms by which hypoxia influences NET behaviour remain poorly understood.

Conference:

Presenting Author:

Authors: Xu L, Yu P, Ye M, Chen J, Tang Q,

Keywords: Neuroendocrine tumour, hypoxia, HIF-1α, VEGF, mTOR, PI3K/AKT, drug resistance, EMT,

#4337 Differences in plasma concentrations of selected growth factors in endocrine neoplasms – A pilot study

Introduction: Serum levels of growth factors associated with endocrine tumours may be potentially useful in detecting their recurrence.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Kurzynska A, Morawiec-Slawek K, Stefanska A, Kolasa M,

Keywords: growth factor, endocrine tumour, TNF-α, Fascin, recurrence risk,

#4301 Case report on the effectiveness of combination therapy in highly aggressive resistant prolactinoma

Introduction: Prolactinomas represent 50% of pituitary neuroendocrine tumours (PitNET), aggressive prolactinomas represent 15% of them.

Conference:

Presenting Author:

Authors: Asanova A, Shutova A, Pigarova E, Dzeranova L,

Keywords: prolactinoma, IHC, Pit Net, chemotherapy,